{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0000879407","name":"ARROWHEAD PHARMACEUTICALS, INC.","summary":"Arrowhead Pharmaceuticals develops RNAi-based medicines that silence disease-causing genes using its proprietary TRiM platform. The company has 18 drug candidates in clinical trials (Phase 1 through Phase 3) and achieved its first FDA-approved product, REDEMPLO (plozasiran), in 2025 for Familial Chylomicronemia Syndrome. Arrowhead has licensed multiple programs to partners including Amgen, Takeda, GSK, and Novartis, while retaining commercialization rights for key pipeline assets.","people":[],"products":[{"name":"REDEMPLO (plozasiran)","type":"platform","description":"FDA-approved siRNA therapeutic targeting APOC3 to reduce triglycerides in adults with Familial Chylomicronemia Syndrome."},{"name":"Plozasiran (ARO-APOC3) for sHTG","type":"platform","description":"Investigational siRNA targeting APOC3 for severe hypertriglyceridemia; Phase 3 trials fully enrolled."},{"name":"Zodasiran (ARO-ANG3)","type":"platform","description":"Investigational siRNA targeting ANGPTL3 for Homozygous Familial Hypercholesterolemia; in Phase 3 YOSEMITE trial."},{"name":"ARO-DIMER-PA","type":"platform","description":"Dual-functional RNAi molecule targeting PCSK9 and APOC3 simultaneously for mixed hyperlipidemia; Phase 1/2a regulatory filing submitted."},{"name":"ARO-PNPLA3","type":"platform","description":"Investigational RNAi therapeutic targeting PNPLA3 for MASH; previously licensed to Janssen, completed two Phase 1 trials."},{"name":"ARO-INHBE","type":"platform","description":"Investigational siRNA targeting INHBE/Activin E for obesity; currently in Phase 1/2a trial."},{"name":"ARO-ALK7","type":"platform","description":"Investigational siRNA targeting ACVR1C/ALK7 in adipocytes for obesity; currently in Phase 1/2a trial."},{"name":"ARO-RAGE","type":"platform","description":"Investigational siRNA targeting RAGE for inflammatory pulmonary disease."},{"name":"TRiM Platform","type":"platform","description":"Proprietary Targeted RNAi Molecule platform enabling ligand-mediated, tissue-specific siRNA delivery to seven cell types."}],"partnerships":[{"partner_name":"Sarepta Therapeutics, Inc.","partnership_type":"licensing","description":"License and collaboration agreement for programs Arrowhead does not intend to commercialize independently.","start_date":null},{"partner_name":"Amgen Inc.","partnership_type":"licensing","description":"License and collaboration agreement for programs Arrowhead does not intend to commercialize independently.","start_date":null},{"partner_name":"Takeda Pharmaceutical Company Limited","partnership_type":"licensing","description":"License and collaboration agreement for programs Arrowhead does not intend to commercialize independently.","start_date":null},{"partner_name":"Glaxosmithkline Intellectual Property (No. 3) Limited","partnership_type":"licensing","description":"License and collaboration agreement for programs Arrowhead does not intend to commercialize independently.","start_date":null},{"partner_name":"Novartis Pharma AG","partnership_type":"licensing","description":"License and collaboration agreement for programs Arrowhead does not intend to commercialize independently.","start_date":null},{"partner_name":"Sanofi","partnership_type":"licensing","description":"Greater China rights for plozasiran out-licensed to Sanofi.","start_date":null},{"partner_name":"Janssen Pharmaceuticals, Inc.","partnership_type":"development","description":"Former licensee that investigated ARO-PNPLA3 in two Phase 1 clinical trials.","start_date":null}],"affiliations":[],"origin":{"leaf":"63976056d3f6c21212cbab94cbe005355f351ab2ffc701cc649b0f5bfea1b439","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"d42e90013fd6f6822f5ccee103bfe418ee35498e6f9ac159bcce95ce5107734f","parent":"7244e63a41c6eb7979681e57cd71a8f66461d348224e50821352fca92fc2886a","source":"0000879407-25-000029","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}